换一批
换一批Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
作者：
主题词
老年人(Aged);饮酒(Alcohol Drinking);血压(Blood Pressure);人体质量指数(Body Mass Index);费用效益分析(Cost-Benefit Analysis);糖尿病并发症(Diabetes Complications);糖尿病, 2型(Diabetes Mellitus, Type 2);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);卫生经费支出(Health Expenditures);人类(Humans);低血糖症(Hypoglycemia);降血糖药(Hypoglycemic Agents);胰岛素(Insulin);脂类(Lipids);男(雄)性(Male);中年人(Middle Aged);挪威(Norway);肽类(Peptides);前瞻性研究(Prospective Studies);生活质量(Quality of Life);质量校正寿命(Quality-Adjusted Life Years);吸烟(Smoking);社会经济因素(Socioeconomic Factors)
DOI
10.3111/13696998.2015.1038271
PMID
25853868
发布时间
2022-12-07
- 浏览51
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
